A citation-based method for searching scientific literature

Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin M Valdes, Elizabeth H Z Thompson, Hervé Bachelez. Lancet 2018
Times Cited: 278







List of co-cited articles
782 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
William J Sandborn, Brian G Feagan, Richard N Fedorak, Ellen Scherl, Mark R Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts. Gastroenterology 2008
558
4

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Alice Gottlieb, Alan Menter, Alan Mendelsohn, Yaung-Kaung Shen, Shu Li, Cynthia Guzzo, Scott Fretzin, Rod Kunynetz, Arthur Kavanaugh. Lancet 2009
431
4

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.
Andrew Blauvelt, Andrea Chiricozzi. Clin Rev Allergy Immunol 2018
235
4

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis.
Vidhatha Reddy, Eric J Yang, Bridget Myers, Wilson Liao. J Inflamm Res 2020
12
33

Risankizumab: First Global Approval.
Kate McKeage, Sean Duggan. Drugs 2019
33
12

The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.
Sarah L Gaffen, Renu Jain, Abhishek V Garg, Daniel J Cua. Nat Rev Immunol 2014
938
4

The global burden of psoriatic skin disease.
K L Goff, C Karimkhani, L N Boyers, M A Weinstock, J P Lott, R J Hay, L E Coffeng, S A Norton, L Naldi, C Dunnick,[...]. Br J Dermatol 2015
54
7

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
K A Papp, C L Leonardi, A Blauvelt, K Reich, N J Korman, M Ohtsuki, C Paul, S Ball, G S Cameron, J Erickson,[...]. Br J Dermatol 2018
60
6

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Craig Leonardi, Robert Matheson, Claus Zachariae, Gregory Cameron, Linda Li, Emily Edson-Heredia, Daniel Braun, Subhashis Banerjee. N Engl J Med 2012
705
4

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
K A Papp, R G Langley, B Sigurgeirsson, M Abe, D R Baker, P Konno, S Haemmerle, H J Thurston, C Papavassilis, H B Richards. Br J Dermatol 2013
271
4

Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
Irina Gasslitter, Natalia Kirsten, Matthias Augustin, Kaspar Torz, Ulrich Mrowietz, Kilian Eyerich, Lluís Puig, Wolfram Hoetzenecker, Martina Schütz-Bergmayr, Wolfgang Weger,[...]. Arch Dermatol Res 2019
23
17

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
Kenneth B Gordon, Richard G Langley, Alice B Gottlieb, Kim A Papp, Gerald G Krueger, Bruce E Strober, David A Williams, Yihua Gu, Joaquin M Valdes. J Invest Dermatol 2012
124
4


Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Hervé Bachelez, Peter C M van de Kerkhof, Robert Strohal, Alexey Kubanov, Fernando Valenzuela, Joo-Heung Lee, Vladimir Yakusevich, Sergio Chimenti, Jocelyne Papacharalambous, James Proulx,[...]. Lancet 2015
260
4

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
Edmund Lee, William L Trepicchio, Judith L Oestreicher, Debra Pittman, Frank Wang, Francesca Chamian, Madhav Dhodapkar, James G Krueger. J Exp Med 2004
662
4

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update.
C H Smith, Z Z N Yiu, T Bale, A D Burden, L C Coates, W Edwards, E MacMahon, S K Mahil, A McGuire, R Murphy,[...]. Br J Dermatol 2020
65
6

Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
A Egeberg, M B Ottosen, R Gniadecki, S Broesby-Olsen, T N Dam, L E Bryld, M K Rasmussen, L Skov. Br J Dermatol 2018
161
4

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
K A Papp, C E M Griffiths, K Gordon, M Lebwohl, P O Szapary, Y Wasfi, D Chan, M-C Hsu, V Ho, P D Ghislain,[...]. Br J Dermatol 2013
287
4

Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Boni Elewski, Alan Menter, Jeffrey Crowley, Stephen Tyring, Yang Zhao, Simon Lowry, Stephen Rozzo, Alan M Mendelsohn, Jeffrey Parno, Kenneth Gordon. J Dermatolog Treat 2020
7
57


Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin. Am J Clin Dermatol 2017
25
16

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
Kim Papp, Herve Bachelez, Antonio Costanzo, Peter Foley, Melinda Gooderham, Primal Kaur, Joanna Narbutt, Sandra Philipp, Lynda Spelman, Jolanta Weglowska,[...]. J Am Acad Dermatol 2017
73
5



Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
R Bissonnette, T Luger, D Thaçi, D Toth, I Messina, R You, A Guana, T Fox, C Papavassilis, I Gilloteau,[...]. Br J Dermatol 2017
40
10

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
Bruce Strober, Alice B Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis,[...]. J Am Acad Dermatol 2017
16
25

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
Sandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, Ignacio Dei-Cas, César Maldonado-García, Elkin O Peñaranda, Luís Puig, Xiangyi Meng, Todd Fox, Adriana Guana. Adv Ther 2017
18
22


Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
K A Papp, K Reich, A Blauvelt, A B Kimball, M Gooderham, S K Tyring, R Sinclair, D Thaci, Q Li, N Cichanowitz,[...]. J Eur Acad Dermatol Venereol 2019
10
40

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
A Blauvelt, K A Papp, H Sofen, M Augustin, G Yosipovitch, N Katoh, U Mrowietz, M Ohtsuki, Y Poulin, D Shrom,[...]. J Eur Acad Dermatol Venereol 2017
42
9


Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.
Andrew Blauvelt, Talia M Muram, Kyoungah See, Craig H Mallinckrodt, Jeffrey J Crowley, Peter van de Kerkhof. J Dermatolog Treat 2018
9
44

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.
Philip J Mease, Philip S Helliwell, Kasper Fjellhaugen Hjuler, Kyle Raymond, Iain McInnes. Ann Rheum Dis 2021
31
12

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
Ulrich Mrowietz, Craig L Leonardi, Giampiero Girolomoni, Darryl Toth, Akimichi Morita, Shyamal A Balki, Jacek C Szepietowski, Pascaline Regnault, Helen Thurston, Charis Papavassilis. J Am Acad Dermatol 2015
140
4

Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.
G Carretero, L Puig, J M Carrascosa, L Ferrándiz, R Ruiz-Villaverde, P de la Cueva, I Belinchon, E Vilarrasa, R Del Rio, J L Sánchez-Carazo,[...]. J Dermatolog Treat 2018
21
19

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
975
4

Psoriasis: epidemiology, clinical features, and quality of life.
R G B Langley, G G Krueger, C E M Griffiths. Ann Rheum Dis 2005
500
4


Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.
Craig A Elmets, Craig L Leonardi, Dawn M R Davis, Joel M Gelfand, Jason Lichten, Nehal N Mehta, April W Armstrong, Cody Connor, Kelly M Cordoro, Boni E Elewski,[...]. J Am Acad Dermatol 2019
146
4

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
Phoebe Rich, Melinda Gooderham, Hervé Bachelez, Joana Goncalves, Robert M Day, Rongdean Chen, Jeffrey Crowley. J Am Acad Dermatol 2016
93
4

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
Eric L Simpson, Carsten Flohr, Lawrence F Eichenfield, Thomas Bieber, Howard Sofen, Alain Taïeb, Ryan Owen, Wendy Putnam, Marcela Castro, Kendra DeBusk,[...]. J Am Acad Dermatol 2018
168
4

Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
Andreas Wollenberg, Michael D Howell, Emma Guttman-Yassky, Jonathan I Silverberg, Christopher Kell, Koustubh Ranade, Rachel Moate, René van der Merwe. J Allergy Clin Immunol 2019
190
4

Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review.
Vijay Kumari Sandhu, Arvin Ighani, Patrick Fleming, Charles W Lynde. J Cutan Med Surg 2020
13
30

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Alan Menter, Kenneth B Gordon, Craig L Leonardi, Yihua Gu, Orin M Goldblum. J Am Acad Dermatol 2010
109
4

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
150
4

Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
Angelo Ruggiero, Gabriella Fabbrocini, Eleonora Cinelli, Matteo Megna. Dermatol Ther 2022
8
50

Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
Zaina T Al-Salama, Lesley J Scott. Am J Clin Dermatol 2018
18
22

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
269
4

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb,[...]. Ann Rheum Dis 2022
10
40

Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.
Najeeda Yasmeen, Laura M Sawyer, Kinga Malottki, Lars-Åke Levin, Eydna Didriksen Apol, Gregor B Jemec. J Dermatolog Treat 2022
17
23


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.